The antiviral wars heat up between Merck, Pfizer, and potentially Roche, as it becomes more apparent to broader segments of the population that a COVID-19 eradication via mass vaccination won’t help society overcome the pandemic—even after hundreds of billions of taxpayer dollars have been spent. CNBC’s Squawk Box discussed this unfolding situation recently with ex-U.S. Food and Drug Administrator (FDA) Scott Gottlieb. Now on Pfizer’s Board, Gottlieb joined CNBC’s Joe Kernan to discuss Pfizer’s antiviral investigational product for COVID-19 currently in clinical trials. Kernan started the show by outright declaring that with so many vaccine nuances, the frustration mounts as it turns out the vaccine isn’t “the panacea we all hoped for….” The host further declared, “it’s not even close.”
With waning effectivity, the delta virus, and powerful viral load leading to rampant breakthrough infections and even breakthrough hospitalization, the Squawk Box host was noticeably honest about the current situation. Of course, Scott Gottlieb, with tenure at the FDA, offers some evidence as to the close dynamics between regulators and industry.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).